Combined Hesperidin and Doxorubicin Treatment Induces Apoptosis and Modulates Inflammatory Cytokines in HeLa Cervical Cancer Cells

Basit Öğe Kaydı
dc.authorid0000-0001-7317-5467
dc.contributor.authorOzdemir, Ilhan
dc.contributor.authorAfsin, Yasemin
dc.contributor.authorTuncer, Mehmet Cudi
dc.contributor.authorOzturk, Samil
dc.date.accessioned2026-02-03T11:59:59Z
dc.date.available2026-02-03T11:59:59Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractCervical cancer is a major gynecological malignancy linked to hormonal dysregulation and genetic alterations. Chemotherapy is standard but limited by toxicity and chemoresistance, prompting interest in plant-derived adjuncts. This study examined the anticancer and immunomodulatory effects of Hesperidin (Hes), a citrus flavonoid, with Doxorubicin (DX) in HeLa cervical cancer cells. Cell viability was assessed by MTT assay, apoptotic markers (Bcl-2, Caspase-3) by RT-qPCR, and inflammatory cytokines (IL-1 beta, IL-6, TNF-alpha, IFN-gamma) by ELISA. Cytokine levels were normalized to 10(4) viable cells, and mRNA expression of all four cytokines was quantified by RT-qPCR, confirming protein-level changes and showing the strongest IL-6 suppression with Hes+DX. Chou-Talalay combination index (CI) analysis demonstrated synergistic interactions (CI < 1.0) between Hes and DX across all tested concentrations, with strong synergism (CI < 0.7) at medium and high doses, particularly at 48 and 72 h. Hes alone showed dose-dependent cytotoxicity, while the combination markedly increased Caspase-3, reduced Bcl-2, and decreased IL-1 beta, IL-6, and TNF-alpha, indicating enhanced intrinsic apoptosis and complementary immunomodulation. These results suggest that Hes augments DX's pro-apoptotic and anti-inflammatory effects, potentially allowing lower chemotherapy doses and reduced systemic toxicity in cervical cancer treatment.
dc.identifier.doi10.3390/ijms26178753
dc.identifier.issn1661-6596
dc.identifier.issn1422-0067
dc.identifier.issue17
dc.identifier.pmid40943673
dc.identifier.scopus2-s2.0-105015894799
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/ijms26178753
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34459
dc.identifier.volume26
dc.identifier.wosWOS:001571363300001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofInternational Journal of Molecular Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20260130
dc.subjectcervical cancer
dc.subjecthesperidin
dc.subjectdoxorubicin
dc.subjectapoptosis
dc.subjectcytokines
dc.subjectHeLa cells
dc.subjectRT-qPCR
dc.subjectcombination therapy
dc.titleCombined Hesperidin and Doxorubicin Treatment Induces Apoptosis and Modulates Inflammatory Cytokines in HeLa Cervical Cancer Cells
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu